# US 2024/0252577 A1 · Composition for inhibiting proliferation of tumor comprising rubus coreanus extract as effective component

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252577 A1
- Document ID: US20240252577A1
- Status: Published application
- Kind: A1
- Application number: 18/290,488
- Filed: 2022-05-31
- Published: 2024-08-01
- Earliest claimed: 2021-08-27
- Assignees: Korea Institute of Oriental Medicine
- Applicants: Korea Institute of Oriental Medicine
- Inventors: HWAN SUCK CHUNG; JI HYE KIM; JANG GI CHOI; EUN-JI LEE; YOUNG SOO KIM
- Web page: https://patentgrep.com/patent/US20240252577A1

## CPC

- A61K 36/73: Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A23L 19/00: Products from fruits or vegetables; Preparation or treatment thereof (marmalades, jams, jellies or the like A23L21/10; treating harvested fruit or vegetables in bulk A23N)
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2236/331: using water, e.g. cold water, infusion, tea, steam distillation or decoction
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for inhibiting proliferation of tumor comprising Rubus coreanus extract as effective component. It was found that the Rubus coreanus extract binds to PD-L1 present on the surface of cancer cells, thus blocking the interaction between cancer cells and PD-1 on the surface of T cells to activate T cells and exhibit an inhibitory effect on tumor proliferation, and it was also found that the Rubus coreanus extract shows an excellent anti-tumor immune activity in humanized PD-1 animal model induced with MC38 colorectal cancer expressing human PD-L1 and also a synergistic effect when co-administered with anti-cancer agents.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method for inhibiting immune checkpoint, the method comprising administering to a subject in need thereof a composition comprising a Rubus coreanus extract as an effective component.

### Claim 14 (depends on 13)

The method of claim 13, wherein the Rubus coreanus extract is prepared by using an extraction solvent selected from the group consisting of water, C1-C4 lower alcohol, and a mixture thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the immune checkpoint is PD-L1 and/or CD80 on a cancer cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer cell is derived from any one of liver cancer, lung cancer, breast cancer, melanoma, stomach cancer, colorectal cancer, rectal cancer, skin cancer, bladder cancer, prostate cancer, ovarian cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, and hematologic malignancy.

### Claim 17

A method for treating a disorder relating to an immune checkpoint inhibition, the method comprising administering to a subject in need thereof a composition comprising a Rubus coreanus extract as an effective component.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disorder is cancer, infection, sepsis, and/or immunosenescence.

### Claim 19 (depends on 17)

The method of claim 17, wherein the disorder is cancer selected from the group consisting of liver cancer, lung cancer, breast cancer, melanoma, stomach cancer, colorectal cancer, rectal cancer, skin cancer, bladder cancer, prostate cancer, ovarian cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, and hematologic malignancy.

### Claim 20 (depends on 17)

The method of claim 17, wherein the composition further comprises an anti-cancer active agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein the anti-cancer active agent is an anti-cancer agent or an immune checkpoint inhibitor.

### Claim 22 (depends on 20)

The method of claim 20, wherein the anti-cancer active agent is an anti-cancer agent selected from the group consisting of actinomycin D, bleomycin sulfate, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitomycin-C, mitramycin, irinotecan, camptothecin, novobiocin, epirubicin, dactinomycin, amsacrine, teniposide, etoposide, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, gefitinib, erlotinib, afatinib, and a combination thereof.

### Claim 23 (depends on 20)

The method of claim 20, wherein the anti-cancer active agent is an immune checkpoint selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CD-80 antibody, an anti-CTLA-4 antibody, and a combination thereof.
